Bharat Srinivasa
Angel Investor @ Amplitude Venture Capital
Toronto, Canada
Bharat Srinivasa is a seed investor at Amplitude Venture Capital in Toronto focused on Therapeutics and Biotechnology. Dr. Bharat Srinivasa serves as Analyst, Healthcare Venture Fund at BDC Healthcare Venture. He joined BDC Capital in 2015.Before this, he was an associate in the forecasting and valuation practice at Foster Rosenblatt, an international advisory firm focused exclusively on life sciences. Bharat was responsible for providing forecasting, commercialanalytics and pricing & market access analysis.Bharat holds a Bachelor of Science in Biotechnology from the University of Toronto and a Master of Science in Microbiology and Immunology from McGill. He also completed his PhD in Experimental Medicine at McGill University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Bharat Srinivasa invests in
Stages Bharat Srinivasa invests in
Countries Bharat Srinivasa invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Health Care 1 (20%)
Stage
- Seed 2 (40%)
- Series A 1 (20%)
- Series B 1 (20%)
Country
- Canada 2 (40%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M / Series B / Jan 07, 2026 | ||
| Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | $12M / Seed / Feb 19, 2025 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $35M / Series A / Sep 11, 2024 | ||
| Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | Seed / Nov 15, 2023 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $8M / Seed / Apr 25, 2023 |
Co-Investors
Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal,Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.
Amplitude Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Mee
Principal
|
|||
Allyson Tighe
Co-Founder & Investor
|
|||
Jean-François Pariseau
Co-Founder and Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bharat Srinivasa invest in?
Bharat Srinivasa invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bharat Srinivasa?
Public channels for Bharat Srinivasa include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bharat Srinivasa last invest?
The most recent investment recorded for Bharat Srinivasa closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
